References
- Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for Hodgkin Lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008; 49: 1485–1492
- Aleman B M, van den Belt-Dusebout A W, De Bruin M L, van't Veer M B, Baaijens M H, de Boer J P, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878–1863
- Hoppe R. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997; 8: 115–118
- Mauch P, Kalish L A, Marcus K C. Long-term survival in Hodgkin's disease: relative impact of mortality, second tumors, infection and cardiovascular disease. Cancer J Sci Am 1995; 1: 33–42
- Moser E, Noordijk E, van Leeuwen F, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin's lymhoma. Blood 2006; 107: 2912–2929
- Ewer M, Lenihan D. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Onc 2008; 26: 1201–1203
- Swerdlow A J, Higgins C D, Smith P, Cunningham D, Hancock B W, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99: 206–214
- Glanzmann C, Kaufmann P, Jenni R, Hess O M, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1998; 46: 51–62
- Ferme C, Eghbali H, Meerwaldt J H, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916–1927
- Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79: 270–277
- Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107–2116